🇺🇸 FDA
Patent

US 6696407

Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF

expired A61KA61K31/00A61K31/198

Quick answer

US patent 6696407 (Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF) held by The Regents of the University of California expires Mon Feb 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Feb 24 2004 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/00, A61K31/198, A61K31/502